Approximately one-third of patients with hypertension have “low-renin hypertension,”1 and such patients are more likely to be salt-sensitive and may respond better to diuretic therapy.2–4 The spectrum of low-renin hypertension includes patients with normokalemic primary hyperaldosteronism (mostly idiopathic hyperaldosteronism), which occurs in up to 15% of hypertensive subjects5–8 and may represent an end-stage in the evolution of neurohormonal changes in “essential” hypertension.7,8 Despite early evidence that patients with low renin levels might have a relatively favorable prognosis,1,9 more recent epidemiological studies suggest that patients with low-renin and/or salt-sensitive hypertension have increased risk of end-organ damage, cardiovascular events, and mortality compared with other hypertensives.3,10–12

These observations might seem difficult to reconcile with our current understanding of the vascular consequences of neurohormonal activation. For example, experimental and clinical studies strongly suggest that activation of the renin-angiotensin-aldosterone system leads to endothelial dysfunction,13,14 which contributes importantly to the pathogenesis of cardiovascular events in hypertension.15,16 In this regard, treatment with angiotensin II, aldosterone, or deoxycorticosterone and salt in rats reduces the bioavailability of endothelium-derived NO, increases superoxide production, and produces other pathological changes in the vasculature.17–19 In humans, patients with elevated aldosterone levels20,21 or renovascular hypertension20 have impaired endothelium-dependent vasodilation in forearm microvessels, and intra-arterial aldosterone infusion impairs endothelium-dependent vasodilation.22 Finally, treatment of hypertensive patients with angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and aldosterone receptor blockers generally improves endothelial function in hypertensive patients, providing further support for a link between endothelial dysfunction and increased activity of the renin-angiotensin system in hypertension.21,23

On the basis of this experimental and clinical work, we hypothesized that increased activity of the renin-aldosterone system would be associated with endothelial dysfunction. The present study investigated this hypothesis in forearm mi-
crovessels of normotensive and hypertensive patients. Our finding that lower, rather than higher, renin activity is associated with endothelial dysfunction in hypertensive patients was unexpected, but may be explained by the observation that patients with relative aldosterone excess in the setting of low renin activity have impaired function. These findings are consistent with available epidemiological evidence and may support the adverse effects of relative hyperaldosteronism among patients with essential hypertension.

Methods

Study Participants

We prospectively recruited patients with a clinical history of hypertension (on treatment and/or systolic blood pressure >140 mm Hg and/or diastolic blood pressure >90 mm Hg) and normotensive volunteers by advertisement. Race was defined by self-report. Volunteers were excluded if they had a history of coronary artery disease, congestive heart failure, peripheral vascular disease, diabetes mellitus (on hypoglycemic medications or with a fasting glucose >140 mg/dL), serum low-density lipoprotein >190 mg/dL, or end-stage renal disease.24 All participants provided written informed consent as approved by the institutional review board of Boston Medical Center.

Study Protocol

Participants discontinued all vasoactive medications for 48 hours before study. In addition, we asked participants to fast overnight and refrain from alcohol, caffeine, and cigarette smoking (if applicable) for at least 12 hours before study. The studies were performed in a quiet, dimmed, temperature-controlled vascular laboratory (24°C). Using sterile conditions and local anesthesia, a 20-gauge polyethylene catheter (Arrow International) was inserted in the nondominant brachial artery for measurement of blood pressure and infusion of drugs. After catheter insertion, 5% dextrose in water (Baxter Healthcare Co) was infused at 0.4 mL/min for at least 30 minutes while stable baseline flow and blood pressure conditions were established. Forearm blood flow was measured by venous occlusion plethysmography with calibrated mercury-in-silastic strain gauges and automatic venous-cuff occlusion at 40 mm Hg (Hokanson, Inc), as previously described.25-26

Serial 5-minute infusions of methacholine (0.3, 1.0, 3.0, and 10 µg/min; Metapharm, Inc), sodium nitroprusside (0.3, 1.0, 3.0, and 10 µg /min; Baxter Anesthesia and Critical Care), or verapamil (10, 30, 100, and 300 µg/min; Abbott Hospital Products) were delivered into the brachial artery. Forearm blood flow was measured during the last 2 minutes of each infusion. Dextrose control was infused for 30 minutes between agonists to reestablish control conditions. The order of drugs was randomized, but not all participants had all agonists.

Biochemical Analyses

Arterial blood samples were collected from the brachial artery catheter into Vacutainer tubes after the participants lay in a supine position for at least 15 minutes. Serum total cholesterol, high-density lipoprotein cholesterol, triglycerides, glucose, and creatinine were measured using an automated analyzer (Hitachi model 917; Hitachi Instruments). LDL cholesterol was calculated using the Friedewald formula.27 Serum aldosterone levels and plasma renin activity (blood anticoagulated with ethylene diamine tetra-acetic acid) were measured using immunochemiluminescence and radioimmunoassay on a commercial basis by Quest Diagnostics, Inc.

Statistical Analysis

We completed separate analyses of patients with hypertension and normotensive healthy volunteers. For each analysis, we categorized participants according to quartile of renin activity and compared clinical characteristics using the χ² test or 1-way ANOVA for categorical and continuous variables, respectively. We examined forearm blood flow responses to methacholine and sodium nitroprusside by quartile of renin activity, quartile of aldosterone to renin ratio, or hypertension status (present or absent) using 2-way repeated measures ANOVA. We completed a similar analysis using the renin cutpoint of 1 ng/mL per hour, which is commonly used clinically to define renin status.21,28 Post hoc comparisons were made using least significant difference testing. The relation between verapamil responses and renin status was examined using the renin activity cutpoint of 1 ng/mL per hour rather than quartile, because of smaller sample size. Among the measured clinical characteristics, only serum creatinine varied significantly by quartile of renin status in hypertensive patients and, for this reason, we also completed an analysis of the relation between forearm blood responses and quartile of renin status with serum creatinine level included as a covariate in the model. Statistical analyses were performed using SPSS for Windows version 12.0 (SPSS Inc). Data are mean±SD, except in the Figures (mean±SE), and P<0.05 was considered significant.

Results

Baseline Clinical Characteristics

We enrolled 43 patients with hypertension and 87 normotensive controls. The clinical characteristics of these 2 groups of participants according to quartile of plasma renin activity are presented in Tables 1 and 2, respectively. There was no significant difference in the duration of hypertension in the 4 quartiles. No patient had clinical evidence of target organ damage. Among hypertensive patients (Table 1), we observed a wide range of plasma renin activities (0.1 to 4.6 ng/mL per hour); however, there were no significant relations between quartile of renin activity and age, gender, body mass index, blood pressure, or lipids, except that HDL tended to decrease with increasing renin activity. Patients in the lowest quartile of renin activity had lower serum creatinine levels than the other 3 quartiles. Interestingly, serum aldosterone level did not differ according to quartile of renin activity but, as expected,4,21 there was a graded reduction in the aldosterone/renin ratio with increasing renin activity.

Among normotensive participants (Table 2), we also observed a wide range of plasma renin activities (0.2 to 12.5 ng/mL per hour). Clinical characteristics were similar among the quartiles of renin activity. However, systolic and diastolic blood pressures were inversely related to renin activity. In this group of normotensive participants, serum aldosterone levels were highest in the highest quartile of plasma renin activity, but there was not a graded increase across quartiles. As expected, we observed a graded decrease in aldosterone to renin ratio with increasing quartile of renin activity.

Comparison of Vascular Function in Hypertensive and Normotensive Participants

Methacholine, sodium nitroprusside, and verapamil produced dose-dependent increases in forearm blood flow in both groups. As has been previously reported,20,25,29 the response to peak methacholine was lower in hypertensive patients compared with normotensives (13.0±6.3 versus 16.0±7.2 mL/min per dL tissue, respectively; P=0.01). In contrast, the response to peak dose of sodium nitroprusside was similar in hypertensive and normotensive subjects (11.1±5.1 and 13.2±5.6 mL/min per dL, respectively; P=0.10). The response to peak dose of verapamil was similar in the 2 groups (13.2±8.7 and 14.4±6.7 mL/min per dL tissue, respectively; P=0.62).
Because the hypertensive group was older than the controls, we selected an age-comparable group of hypertensive (n=41, aged 50±11 years) and normotensive (n=42, aged 48±9 years) participants. Despite being comparable in age, hypertensive patients had higher body mass index and serum triglycerides, and tended to have higher total cholesterol and low-density lipoprotein levels. They also had lower high-density lipoprotein levels; findings consistent with the hypertension-associated metabolic syndrome.30 As for the group as a whole, patients with hypertension had impaired endothelium-dependent responses to methacholine compared with age-matched normotensive controls (13.4±6.2 versus 15.9±6.5 mL/min per dL for the peak response; \( P=0.013 \)). However, their responses to the endothelium-independent vasodilator sodium nitroprusside were preserved (11.4±5.0 versus 12.9±5.7 mL/min per dL for the peak response; \( P=0.54 \)).

### TABLE 1. Hypertensives by Quartile of Renin Activity

<table>
<thead>
<tr>
<th>Parameter</th>
<th>1 (0.1–0.3)</th>
<th>2 (0.4–0.8)</th>
<th>3 (0.9–1.8)</th>
<th>4 (1.9–4.6)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>No.</td>
<td>10</td>
<td>11</td>
<td>11</td>
<td>11</td>
<td></td>
</tr>
<tr>
<td>Age (y)</td>
<td>54±14</td>
<td>52±9</td>
<td>51±13</td>
<td>48±12</td>
<td>0.63</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>29±5</td>
<td>30±7</td>
<td>30±5</td>
<td>29±5</td>
<td>0.92</td>
</tr>
<tr>
<td>Female, n (%)</td>
<td>4 (40%)</td>
<td>5 (45%)</td>
<td>4 (36%)</td>
<td>3 (27%)</td>
<td>0.84</td>
</tr>
<tr>
<td>Black, n (%)</td>
<td>5 (50%)</td>
<td>6 (55%)</td>
<td>3 (27%)</td>
<td>3 (27%)</td>
<td>0.41</td>
</tr>
<tr>
<td>Systolic BP (mm Hg)</td>
<td>152±24</td>
<td>158±15</td>
<td>145±8</td>
<td>143±21</td>
<td>0.23</td>
</tr>
<tr>
<td>Diastolic BP (mm Hg)</td>
<td>91±16</td>
<td>98±15</td>
<td>95±11</td>
<td>91±11</td>
<td>0.57</td>
</tr>
<tr>
<td>Total cholesterol (mg/dL)</td>
<td>191±48</td>
<td>216±41</td>
<td>189±26</td>
<td>197±36</td>
<td>0.36</td>
</tr>
<tr>
<td>LDL (mg/dL)</td>
<td>115±39</td>
<td>138±44</td>
<td>110±31</td>
<td>125±28</td>
<td>0.30</td>
</tr>
<tr>
<td>HDL (mg/dL)</td>
<td>52±12</td>
<td>49±15</td>
<td>47±11</td>
<td>38±7</td>
<td>0.03</td>
</tr>
<tr>
<td>Triglycerides (mg/dL)</td>
<td>117±61</td>
<td>145±114</td>
<td>162±106</td>
<td>174±85</td>
<td>0.55</td>
</tr>
<tr>
<td>Glucose (mg/dL)</td>
<td>101±29</td>
<td>107±24</td>
<td>99±11</td>
<td>107±13</td>
<td>0.72</td>
</tr>
<tr>
<td>Creatinine (mg/dL)</td>
<td>0.66±0.17</td>
<td>0.85±0.18</td>
<td>0.96±0.20</td>
<td>0.82±0.21</td>
<td>0.008</td>
</tr>
<tr>
<td>Renin (ng/mL per hour)</td>
<td>0.20±0.05</td>
<td>0.49±0.12</td>
<td>1.25±0.31</td>
<td>2.63±0.78</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Aldosterone (ng/dL)</td>
<td>9.9±8.5</td>
<td>7.8±3.4</td>
<td>8.8±4.5</td>
<td>10.9±6.3</td>
<td>0.64</td>
</tr>
<tr>
<td>Aldosterone/renin</td>
<td>51.7±42.4</td>
<td>16.6±7.4</td>
<td>7.1±3.3</td>
<td>4.3±2.6</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

Data are mean±SD. P value refers to overall ANOVA. BMI indicates body mass index; BP, blood pressure.

### TABLE 2. Normotensives by Quartile of Renin Activity

<table>
<thead>
<tr>
<th>Parameter</th>
<th>1 (0.2–0.6)</th>
<th>2 (0.6–1.0)</th>
<th>3 (1.1–1.8)</th>
<th>4 (2.0–12.5)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>No.</td>
<td>22</td>
<td>22</td>
<td>22</td>
<td>21</td>
<td></td>
</tr>
<tr>
<td>Age (y)</td>
<td>39±13</td>
<td>39±14</td>
<td>34±13</td>
<td>39±13</td>
<td>0.59</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>27±5</td>
<td>27±5</td>
<td>25±4</td>
<td>26±5</td>
<td>0.53</td>
</tr>
<tr>
<td>Female, n (%)</td>
<td>9 (41%)</td>
<td>8 (36%)</td>
<td>10 (45%)</td>
<td>7 (33%)</td>
<td>0.86</td>
</tr>
<tr>
<td>Black, n (%)</td>
<td>15 (68%)</td>
<td>11 (50%)</td>
<td>8 (36%)</td>
<td>9 (43%)</td>
<td>0.18</td>
</tr>
<tr>
<td>Systolic BP (mm Hg)</td>
<td>129±15</td>
<td>122±12</td>
<td>118±11</td>
<td>119±11</td>
<td>0.02</td>
</tr>
<tr>
<td>Diastolic BP (mm Hg)</td>
<td>79±10</td>
<td>76±10</td>
<td>74±9</td>
<td>70±10</td>
<td>0.04</td>
</tr>
<tr>
<td>Total cholesterol (mg/dL)</td>
<td>165±34</td>
<td>170±31</td>
<td>178±35</td>
<td>184±32</td>
<td>0.24</td>
</tr>
<tr>
<td>LDL (mg/dL)</td>
<td>96±28</td>
<td>105±27</td>
<td>104±30</td>
<td>116±30</td>
<td>0.16</td>
</tr>
<tr>
<td>HDL (mg/dL)</td>
<td>50±17</td>
<td>47±12</td>
<td>54±17</td>
<td>50±14</td>
<td>0.52</td>
</tr>
<tr>
<td>Triglycerides (mg/dL)</td>
<td>96±61</td>
<td>91±51</td>
<td>106±81</td>
<td>92±47</td>
<td>0.85</td>
</tr>
<tr>
<td>Glucose (mg/dL)</td>
<td>101±17</td>
<td>93±15</td>
<td>101±28</td>
<td>98±16</td>
<td>0.47</td>
</tr>
<tr>
<td>Creatinine (mg/dL)</td>
<td>0.83±0.20</td>
<td>0.77±0.22</td>
<td>0.80±0.21</td>
<td>0.75±0.14</td>
<td>0.55</td>
</tr>
<tr>
<td>Renin (ng/mL per hour)</td>
<td>0.39±0.13</td>
<td>0.78±0.15</td>
<td>1.35±0.25</td>
<td>3.75±2.52</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Aldosterone (ng/dL)</td>
<td>7.8±6.4</td>
<td>7.4±2.6</td>
<td>6.6±2.3</td>
<td>12.3±6.5</td>
<td>0.001</td>
</tr>
<tr>
<td>Aldosterone/renin</td>
<td>23.9±27.6</td>
<td>9.7±3.6</td>
<td>5.0±2.0</td>
<td>4.1±2.9</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

Data are mean±SD. P value refers to overall ANOVA.
Renin Status and Vascular Function

Figure 1 displays the forearm blood flow responses to methacholine and nitroprusside in patients with hypertension. As shown, those in the lowest quartile of renin activity had markedly impaired endothelium-dependent responses to peak methacholine compared with patients in the other three quartiles (8.7±7.3 versus 13.8±5.1, 13.7±6.5, and 15.1±5.3 mL/min per dL, respectively; \(P<0.001\)). These low-renin hypertensive patients also had markedly impaired responses to the peak dose of the nitric oxide donor sodium nitroprusside (5.6±2.1 versus 13.1±4.0, 13.1±5.4, and 13.8±2.9 mL/min per dL, respectively; \(P<0.001\)). By contrast, normotensive, healthy controls had similar responses in all 4 quartiles of renin activity to methacholine (\(P=0.34\)) and sodium nitroprusside (\(P=0.34\)) (Figure 2). When patients with hypertension were dichotomized by plasma renin activity above and below 1 ng/mL per hour (a clinical cutoff point for low-renin hypertension),21,28 patients with lower renin activity (n=25) also had markedly impaired responses to the peak dose of the nitric oxide donor sodium nitroprusside (5.6±2.1 versus 13.1±4.0, 13.1±5.4, and 13.8±2.9 mL/min per dL, respectively; \(P<0.001\)). By contrast, normotensive, healthy controls had similar responses in all 4 quartiles of renin activity to methacholine (\(P=0.34\)) and sodium nitroprusside (\(P=0.34\)) (Figure 2). When patients with hypertension were dichotomized by plasma renin activity above and below 1 ng/mL per hour (a clinical cutoff point for low-renin hypertension),21,28 patients with lower renin activity (n=25) also had impaired vasodilator responses to methacholine (11.0±6.4 versus 15.7±5.2 mL/min per dL for the peak response; \(P=0.002\)) and sodium nitroprusside (9.1±4.7 versus 14.1±4.3 mL/min per dL for the peak response; \(P=0.015\)).

To investigate the relation between renin status and non-nitric oxide-dependent vasodilation, we examined the forearm blood flow response to verapamil in 20 patients with hypertension and 40 normotensive controls. Because of the smaller sample size, we again dichotomized the groups using a cutoff point of 1 ng/mL per hour. Among hypertensives, the peak responses to verapamil were 13.6±10.3 and 11.9±4.9 mL/min per dL for the low (n=10) and high (n=10) plasma renin activity groups, respectively (\(P=0.93\)) (Figure 3). Among normotensives, the peak responses to verapamil were 13.9±6.9 and 15.0±6.8 mL/min per dL for the low (n=19) and high (n=21) plasma renin activity groups, respectively (\(P=0.93\)) (Figure 3).

Renal dysfunction is associated with endothelial dysfunction.31 Therefore, we investigated whether variation in renal function confounded our results. As shown in Table 1, we observed that serum creatinine was significantly lower in the lowest quartile of renin activity compared with the other 3 quartiles. Quartile of renin activity remained a significant predictor of the dilator response to peak methacholine dose (\(P=0.04\)) and peak sodium nitroprusside dose (\(P<0.001\)) after adjusting for serum creatinine level. Because serum creatinine was actually lower in the lowest quartile of renin activity, it is unlikely that variation in renal function accounts for the impaired endothelium-dependent or endothelium-independent dilation in the lowest quartile of renin activity.
Aldosterone to Renin Ratio and Vascular Function

We observed no relation between quartile of serum aldosterone level and vasodilator response to methacholine, sodium nitroprusside, or verapamil (data not shown). However, a high aldosterone to renin ratio reflects “inappropriate” elevation of aldosterone level for a given level of renin activity. This variable has been used as a screen for adrenal adenomas and hyperplasia and may be moderately elevated in low-renin hypertension (30 to 100 ng/dL per ng/mL per hour). We therefore investigated the relation between quartile of aldosterone to renin ratio and vascular function in hypertensive and normotensive participants. In the hypertensive group, patients with the highest quartile of aldosterone to renin ratio (19.7 to 155 ng/dL per ng/mL per hour) had lower vasodilator responses to peak methacholine (9.5 ± 7.3 mL/min per dL) compared with the first, second, and third quartiles (15.0 ± 5.9, 14.1 ± 5.9, and 12.8 ± 6.3 mL/min per dL, respectively, P < 0.001) (Figure 4). However, there was no significant relation between quartile of aldosterone to renin ratio and the vasodilator response to sodium nitroprusside (Figure 4).

Discussion

In this study, hypertensive patients in the lowest quartile of plasma renin activity had markedly impaired forearm blood flow responses to methacholine and sodium nitroprusside compared with patients in the other three quartiles. This relation between plasma renin activity and vascular function was not observed in normotensive participants. Furthermore, there was no relation between renin status and the vasodilator responses to verapamil in hypertensive or normotensive participants. Because methacholine is a stimulus for production of endothelium-derived nitric oxide and sodium nitroprusside is a nitric oxide donor, these findings are consistent with the possibility that patients with low-renin hypertension have a selective defect in nitric oxide-dependent vasodilation. The preserved vasodilator responses to the calcium channel blocker verapamil argue against a generalized impairment of vasodilator function in hypertensive patients with low renin status. Finally, we observed that hypertensive patients in the highest quartile of aldosterone to renin ratio had the most impaired vasodilator function, raising the possibility that relative aldosterone excess in low-renin hypertension might lead to a reduction in the biological activity of nitric oxide.

Based on animal and human studies, we had hypothesized that hypertensive patients with the highest rather than the lowest plasma renin activity would display the most severe degree of vasodilator dysfunction. However, the present findings are not entirely inconsistent with previous work. For example, patients with salt-sensitive hypertension tend to have low renin activity, and Bragulat et al observed impaired vasodilator responses to acetylcholine and preserved vasodilator responses to sodium nitroprusside.
In patients with salt-sensitive hypertension, nitroprusside was effective in reducing blood pressure. In addition, Omland et al did not detect endothelial dysfunction in volunteers in whom plasma renin activity was increased from 1.0 ± 0.5 to 5.0 ± 2.5 ng/mL per hour by 5 days of a low-salt diet. In the present study, renin activity in the highest quartile was 1.9 to 4.6 ng/mL per hour, and it remains possible that patients with more marked elevations of plasma renin activity might display impaired vasodilator function. Although the relation between high renin status and vascular dysfunction in humans remain speculative, the present study points to a marked impairment of nitric oxide-dependent dilation with patients with the lowest renin activity.

Both experimental and clinical studies support that possibility that relative aldosterone excess might account for our findings. In rats, mineralocorticoid treatment (aldosterone or deoxycorticosterone acetate) is associated with low renin activity and endothelial dysfunction. Consistent with those observations, patients with hyperaldosteronism also display endothelial dysfunction. For example Nishizaka et al observed impaired flow-mediated dilation of the brachial artery in patients with hyperaldosteronism and a mean aldosterone to renin ratio (44.7 ± 29.5) that is comparable to the ratio in the patients in our highest quartile (55.1 ± 39.4). Taddei et al also observed impaired endothelial function in forearm microvessels of patients with primary hyperaldosteronism. Additionally, treatment with an aldosterone antagonist has been shown to reverse endothelial dysfunction in patients with hypertension and congestive heart failure. Finally, acute intra-arterial infusion of aldosterone into the forearm of healthy volunteers impaired the dilator response to acetylcholine, but not to sodium nitroprusside, further supporting a link between elevated aldosterone levels and endothelial dysfunction.

The present study did not examine the mechanisms that might account for vascular dysfunction in patients with low-renin hypertension or a relative increase in aldosterone activity. However, extensive experimental studies have documented increased vascular production of superoxide anion in models of low-renin hypertension. Furthermore, administration of superoxide dismutase corrects vascular dysfunction under these conditions. The stimulus for increased production of superoxide in aldosterone-induced hypertension is not clear. However, aldosterone-induced hypertension is associated with activation of NADPH oxidase and endothelial dysfunction in experimental models, and these effects are reversed by spironolactone. In addition, recent studies suggest that aldosterone may increase endothelin-1 production, which may also stimulate superoxide production by NADPH oxidase in the arterial wall. Aldosterone and endothelin-1 may stimulate local arterial inflammation that may be associated with production of reactive oxygen species and/or consumption of nitric oxide. Arterial remodeling and fibrosis in this setting may perpetuate vascular dysfunction and hypertension. Thus, a state of relative aldosterone excess in low-renin hypertension has the potential to impair nitric oxide-dependent vasodilation by increasing oxidative stress and by promoting local inflammation and remodeling.

Our study has a number of limitations. For example, assessment of plasma renin activity and aldosterone levels were performed after a relatively short period in a supine position and without adjustment for salt intake. However, all participants were consuming typical American diets and may be assumed to be salt replete. Unmeasured variation because of posture or salt intake would have tended to obscure differences between groups and are unlikely to explain the marked impairment in vascular function observed in patients with the lowest renin activity. We were not able to formally exclude primary hyperaldosteronism in our subjects. The study is further limited because verapamil-induced vasodilation was only examined in a subset of patients. However, there was no apparent trend for impaired vasodilator responses in patients with lower renin activity. Strengths of our study include a relatively large sample size for an invasive study of endothelial function, the use of multiple doses of specific agonists for endothelium- and nitric oxide-dependent vasodilation, and the marked impairment in vasodilator function in the patients with low renin. Thus, we have demonstrated impaired nitric oxide-mediated vasodilation in patients with low-renin hypertension and in those with inappropriately raised aldosterone levels. Additional studies will be required to define the mechanisms accounting for these observations.

**Perspectives**

The present study may have a number of important clinical implications. Low-renin hypertension is associated with worse end organ damage and a worse prognosis compared with other hypertensive patients. Inappropriately elevated aldosterone levels in this setting is a common finding and has piqued interest in normokalemic primary hyperaldosteronism, which has recently been hypothesized to represent an "end stage" of neurohormonal activation in hypertension. This contention is consistent with the observations that salt-sensitivity, low-renin status, increased adrenal sensitivity to angiotensin II, increased aldosterone/renin ratios, and endothelial dysfunction are all seen with advancing age. Endothelial dysfunction and the loss of the biological activity of endothelium-derived nitric oxide may contribute to the pathogenesis and clinical expression of cardiovascular disease and to adverse arterial and left ventricular remodeling. Furthermore, endothelial dysfunction and its failure to improve with antihypertensive treatment identifies hypertensive patients at high risk for cardiovascular events. Thus, our finding that nitric oxide-dependent dilation is impaired in hypertensive patients with low renin activity and high aldosterone to renin ratio may provide insight into why such patients have increased risk. Targeting treatments more effectively may improve blood pressure control, endothelial function, and prognosis. For example, spironolactone or eplerenone appear to be particularly efficacious in hypertension associated with increased aldosterone/renin ratios and could have particularly favorable effects on the vascular wall. Thus, our findings are consistent with the growing recognition that low-renin hypertension and aldosterone excess represent an end stage of neurohormonal activation in essential hypertension and may provide insight into why such patients have a worse prognosis. In addition, the findings may provide further rationale for targeting antihypertensive therapy to neurohormonal status.

**Acknowledgments**

S.J.D. is supported by a career development award (182830) and a project grant (225107) from the National Health and Medical Research Council.
Research Council of Australia. J.A.V. is supported by a Specialized Center of Research Grant (HL55993), the Boston Medical Center General Clinical Research Center (M01RR00533), and National Institutes of Health grant (HL60886).

References


18. Zhou MS, Adam AG, Jaimes EA, Raji L. In salt-sensitive hypertension, increased superoxide production is linked to functional upregulation of angiotensin II. Hypertension. 2003;42:945–951.


Low-Renin Hypertension With Relative Aldosterone Excess Is Associated With Impaired NO-Mediated Vasodilation
Stephen J. Duffy, Elizabeth S. Biegelsen, Robert T. Eberhardt, David F. Kahn, Bronwyn A. Kingwell and Joseph A. Vita

Hypertension. 2005;46:707-713; originally published online September 19, 2005;
doi: 10.1161/01.HYP.0000184231.84465.62
Hypertension is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2005 American Heart Association, Inc. All rights reserved.
Print ISSN: 0194-911X. Online ISSN: 1524-4563

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://hyper.ahajournals.org/content/46/4/707

An erratum has been published regarding this article. Please see the attached page for:
/content/46/6/e26.full.pdf

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Hypertension can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Hypertension is online at:
http://hyper.ahajournals.org//subscriptions/
In an article by S.F. Duffy et al in the October 2005 issue of *Hypertension* (Duffy SF, Biegelsen, ES, Eberhardt, RT, Kahn DF, Kingwell, BA, Vita, JA. Low-renin hypertension with relative aldosterone excess is associated with impaired NO-mediated vasodilation. *Hypertension*. 2005;46:707–713) the lower panel of Figure 4 is incorrect. Whereas the legend and data symbols are correct in the upper panel, the symbols are reversed in the lower panel. As shown in the corrected figure below, the subjects in the highest quartile of aldosterone-to-renin ratio tended to have the lowest response to sodium nitroprusside, however, this response did not differ from the responses of subjects in the other 3 quartiles ($P=0.37$). Overall as reported in the article, there was no significant relation between quartile of aldosterone-to-renin ratio and the vasodilator response to sodium nitroprusside. The authors regret the error.

![Diagram of vascular function by quartile of aldosterone/renin ratio in hypertensive subjects. The forearm blood flow responses to the endothelium-dependent vasodilator methacholine and the endothelium-independent dilator sodium nitroprusside (SNP) are shown in the upper and lower panels, respectively. The vasodilator response to methacholine was lower for subjects in the highest aldosterone-renin ratio quartile (4th aldosterone-renin quartile) compared to subjects in the other 3 quartiles ($P<0.001$), where there was no relation between quartile of aldosterone-renin ratio and the vasodilator response to SNP.]